Drug intelligence / Profile preview

KD2502

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KD2502 is a small molecule therapeutic being developed by Kyungdong Pharmaceutical for the treatment of dyslipidemia. It is classified in the company's pipeline as an 'improved new drug' (incrementally modified drug), a regulatory category in South Korea that typically encompasses new formulations, salts, or fixed-dose combinations of existing active pharmaceutical ingredients. As of late 2025, the project is in the discovery phase, and specific details regarding its molecular target or mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on KD2502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD2502.

Explore the full profile